Effect of prior immunotherapy on the efficacy of chemotherapy in advanced non-small cell lung cancer: A retrospective study.
angiogenesis inhibitors
immune checkpoint inhibitor
non-small cell lung cancer
salvage chemotherapy
sequential treatment
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
revised:
10
03
2022
received:
15
01
2022
accepted:
11
03
2022
pubmed:
19
4
2022
medline:
4
5
2022
entrez:
18
4
2022
Statut:
ppublish
Résumé
The effect of the sequential combination of chemotherapy and immune checkpoint inhibitors (ICIs) remains unclear. Here, we evaluated the efficacy of different chemotherapy regimens administered after ICIs in advanced non-small cell lung cancer (NSCLC), compared to the same regimens administered without previous ICIs. We retrospectively included all patients treated between 2015 and 2019 for an advanced NSCLC, receiving a salvage chemotherapy just after ICI (CAI group) comparing them to ICI naive patients (CWPI group) undergoing the same chemotherapy at Bordeaux University Hospital. The primary outcome was the time to treatment discontinuation (TTD), and secondary endpoints were overall survival (OS) and overall response rate (ORR). A total of 152 patients were included, with 34/23 (CAI/CWPI) receiving paclitaxel/bevacizumab (PB), 24/11 paclitaxel (P), 27/12 gemcitabine (G) and 6/15 pemetrexed (PE). Characteristics were comparable, except for CAI treated with PB (more patients with an ECOG PS ≤1 [p <0.001]). Median number of lines received was higher in CAI for all groups. There was no difference between CAI and CWPI for TTD, OS and ORR. However, PB was associated with a nonsignificant increase in OS in the CAI group (HR = 0.65; 95% CI: 0.38-1.2, p = 0.17]. Our data showed no difference in TTD, OS and ORR regardless of chemotherapy, but a trend towards an increased OS with PB when given after an ICI, while patients received chemotherapy later in the CAI group. This suggests that a sequential combination of ICI followed by chemotherapy could be an interesting strategy in advanced NSCLC for selected patients.
Sections du résumé
BACKGROUND
The effect of the sequential combination of chemotherapy and immune checkpoint inhibitors (ICIs) remains unclear. Here, we evaluated the efficacy of different chemotherapy regimens administered after ICIs in advanced non-small cell lung cancer (NSCLC), compared to the same regimens administered without previous ICIs.
METHODS
We retrospectively included all patients treated between 2015 and 2019 for an advanced NSCLC, receiving a salvage chemotherapy just after ICI (CAI group) comparing them to ICI naive patients (CWPI group) undergoing the same chemotherapy at Bordeaux University Hospital. The primary outcome was the time to treatment discontinuation (TTD), and secondary endpoints were overall survival (OS) and overall response rate (ORR).
RESULTS
A total of 152 patients were included, with 34/23 (CAI/CWPI) receiving paclitaxel/bevacizumab (PB), 24/11 paclitaxel (P), 27/12 gemcitabine (G) and 6/15 pemetrexed (PE). Characteristics were comparable, except for CAI treated with PB (more patients with an ECOG PS ≤1 [p <0.001]). Median number of lines received was higher in CAI for all groups. There was no difference between CAI and CWPI for TTD, OS and ORR. However, PB was associated with a nonsignificant increase in OS in the CAI group (HR = 0.65; 95% CI: 0.38-1.2, p = 0.17].
CONCLUSION
Our data showed no difference in TTD, OS and ORR regardless of chemotherapy, but a trend towards an increased OS with PB when given after an ICI, while patients received chemotherapy later in the CAI group. This suggests that a sequential combination of ICI followed by chemotherapy could be an interesting strategy in advanced NSCLC for selected patients.
Identifiants
pubmed: 35434866
doi: 10.1111/1759-7714.14403
pmc: PMC9058314
doi:
Substances chimiques
Bevacizumab
2S9ZZM9Q9V
Paclitaxel
P88XT4IS4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1391-1400Informations de copyright
© 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
Lung Cancer. 2004 Aug;45(2):227-36
pubmed: 15246195
Clin Med Insights Oncol. 2020 Aug 19;14:1179554920951358
pubmed: 32884390
Cancer Res. 2003 Aug 1;63(15):4490-6
pubmed: 12907622
Am J Clin Oncol. 2020 Feb;43(2):115-121
pubmed: 31809326
Eur J Cancer. 2020 May;131:27-36
pubmed: 32276179
Lung Cancer. 2020 Dec;150:123-131
pubmed: 33130353
J Clin Oncol. 2019 Mar 1;37(7):537-546
pubmed: 30620668
J Immunother Cancer. 2020 Feb;8(1):
pubmed: 32066647
Ther Adv Med Oncol. 2022 Jun 6;14:17588359221099399
pubmed: 35694190
J Clin Oncol. 2020 May 10;38(14):1505-1517
pubmed: 32150489
Sci Rep. 2019 Aug 7;9(1):11472
pubmed: 31391510
J Clin Oncol. 2010 Jul 1;28(19):3167-75
pubmed: 20516446
Nat Rev Clin Oncol. 2018 May;15(5):325-340
pubmed: 29508855
Nat Rev Clin Oncol. 2020 Dec;17(12):725-741
pubmed: 32760014
Eur J Cancer. 2019 Nov;121:123-129
pubmed: 31574417
Ann Oncol. 2003 Nov;14(11):1640-7
pubmed: 14581272
J Clin Oncol. 1999 Jul;17(7):2081-5
pubmed: 10561261
Cancer Immunol Res. 2015 May;3(5):436-43
pubmed: 25941355
Eur Urol. 2018 Feb;73(2):149-152
pubmed: 28917596
Thorac Cancer. 2018 Jan;9(1):175-180
pubmed: 29063735
J Thorac Oncol. 2018 Jan;13(1):106-111
pubmed: 29101058
Thorac Cancer. 2022 May;13(9):1391-1400
pubmed: 35434866
Cancer Cell. 2015 Dec 14;28(6):690-714
pubmed: 26678337
ERJ Open Res. 2018 Apr 20;4(2):
pubmed: 29692997
J Clin Oncol. 2004 May 1;22(9):1589-97
pubmed: 15117980
Am J Hematol. 2018 Jun 8;:
pubmed: 29884994